Patents Assigned to Vermilllion, Inc.
  • BETA-2 MICROGLOBULIN AS A BIOMARKER FOR PERIPHERAL ARTERY DISEASE
    Publication number: 20110151481
    Abstract: The present invention provides ?2 microglobulin as a biomarker for qualifying or assessing peripheral artery disease in a subject.
    Type: Application
    Filed: December 20, 2010
    Publication date: June 23, 2011
    Applicant: VERMILLLION, INC.
    Inventors: John Cooke, Eric T. Fung, Eiichiro Kimura
  • BIOMARKERS FOR THE DETECTION OF EARLY STAGE OVARIAN CANCER
    Publication number: 20100304993
    Abstract: The present invention provides methods and compositions for detecting early stage ovarian cancer in a patient. Also, methods for evaluating the ovarian cancer state of a patient are described herein. These methods involve the detection, analysis, and classification of biomarkers in biological samples.
    Type: Application
    Filed: April 29, 2010
    Publication date: December 2, 2010
    Applicants: VERMILLLION, INC., Board of Regents, The University of Texas System
    Inventors: Eric T. Fung, Charlotte Clarke, Robert C. Bast, JR., Kevin R. Coombes
  • Biomarkers for alzheimer's disease
    Patent number: 7794948
    Abstract: The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying Alzheimer's disease status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as Alzheimer's or non-Alzheimer's dementia or normal. The biomarkers can be detected by SELDI mass spectrometry. In addition, the invention provides appropriate treatment interventions and methods for measuring response to treatment. Certain biomarkers of the invention may also be suitable for employment as radio-labeled ligands in non-invasive imaging techniques such as Positron Emission Tomography (PET).
    Type: Grant
    Filed: November 6, 2004
    Date of Patent: September 14, 2010
    Assignee: Vermilllion, Inc.
    Inventors: Huw Alun Davies, James McGuire, Anja Hviid Simonsen, Kaj Blennow, Vladimir Podust
  • Methods of detecting a fragment of neurosecretory protein VGF for diagnosing alzheimer's disease
    Patent number: 7749716
    Abstract: The present invention provides a neurosecretory protein VGF peptide useful in qualifying Alzheimer's disease status in a patient. In particular, this peptide and modified forms thereof may be used to classify a subject sample as Alzheimer's disease or non-Alzheimer's disease. The peptide biomarker can be detected by SELDI mass spectrometry.
    Type: Grant
    Filed: June 13, 2006
    Date of Patent: July 6, 2010
    Assignee: Vermilllion, Inc.
    Inventors: Huw Alun Davies, Kaj Blennow, James McGuire, Vladimir Podust, Anja Hviid Simonsen
  • Biomaker for ovarian and endometrial cancer: hepcidin
    Publication number: 20100068724
    Abstract: The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status as well as endometrical cancer status in a patient. In particular, it has been found that hepcidin is a biomarker for both ovarian cancer and endometrial cancer and that a panel of biomarkers, including hepcidin, transthyretin and optionally other markers are useful to classify a subject sample as ovarian cancer or non-ovarian cancer. The biomarkers can be detected by SELDI mass spectrometry.
    Type: Application
    Filed: March 9, 2009
    Publication date: March 18, 2010
    Applicants: Vermilllion, Inc., The Johns Hopkins University, Board of Regents, The University of Texas System
    Inventors: Eric T. Fung, Robert Bast, Daniel W. Chan, Jin Song, Valdimir Podust, Zhen Zhang
  • Biomarker for ovarian and endometrial cancer: hepcidin
    Patent number: 7510842
    Abstract: The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status as well as endometrical cancer status in a patient. In particular, it has been found that hepcidin is a biomarker for both ovarian cancer and endometrial cancer and that a panel of biomarkers, including hepcidin, transthyretin and optionally other markers are useful to classify a subject sample as ovarian cancer or non-ovarian cancer. The biomarkers can be detected by SELDI mass spectrometry.
    Type: Grant
    Filed: March 10, 2006
    Date of Patent: March 31, 2009
    Assignees: Vermilllion, Inc., The John Hopkins University, Board of Regents, The University of Texas System
    Inventors: Valdimir Podust, Zhen Zhang, Eric T. Fung, Robert Bast, Daniel W. Chan, Jin Song